Modality
Radioligand
MOA
IL-13i
Target
RET
Pathway
Hedgehog
ETMG
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
Jan 2017
→ Jun 2031
Phase 2Current
NCT06076813
2,072 pts·MG
2025-07→2031-06·Active
NCT03750558
1,716 pts·ET
2017-01→2025-11·Active
3,788 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-214mo agoPh2 Data· ET
2031-06-235.2y awayPh2 Data· MG
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Active
P2
Active
Catalysts
Ph2 Data
2025-11-21 · 4mo ago
ET
Ph2 Data
2031-06-23 · 5.2y away
MG
Active|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-5389 | Roche | Preclinical | RET | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |